Clicky

Biomind Labs Inc(BMND)

Description: Biomind Labs Inc., a biotech research and development company, focuses on developing novel pharmaceutical drugs and nanotech delivery systems for various psychiatric and neurological conditions. The company is developing BMND01, which is in Phase II clinical trials for use in the treatment of depression; and BMND08, a 5-Methoxy-N,N-dimethyltryptamine based candidate that is in Phase II clinical trials for treatment of depression and anxiety in patients with Alzheimer's-type cognitive impairment. It is also developing new and preclinical drug candidates, including BMND02 for treating fibromyalgia, BMND03 for treating addictive disorders, BMND05 for treating chronic pain, BMND06 for treating inflammation, and BMND07 for treating major depressive disorder. The company is headquartered in Canelones, Uruguay.


Keywords: Medicine Inflammation Alzheimer's Disease Depression Psychiatric Diagnosis Chronic Pain Psychiatry Rheumatology Major Depressive Disorder Fibromyalgia Pharmaceutical Drugs Treatment Of Depression Management Of Depression Clinical Neuroscience Addictive Disorders Bmnd01 Bmnd08 Nanotech Delivery Systems Type Cognitive Impairment

Home Page: www.biomindlabs.com

Building Ceibo Of. 002
Canelones,
Uruguay
Phone:


Officers

Name Title
Mr. Alejandro Antalich CEO & Director
Mr. Oscar Alejandro Leon CFO & Director
Ms. Paola Diaz Dellavalle Ph.D. Chief Scientific Officer
Mr. Juan Presa Chief Legal Officer
Ms. Magdalena Alvarez M.A. Head of Communication
Mr. Martin Daners Head of Quality Assurance & Regulatory Affairs
Dr. Marcelo Falchi Head of the Psychiatry Research Unit

Exchange: NEO

Country: CA : Canada

Currency: Canadian Dollar (C$)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 186.6835
Price-to-Sales TTM: 0
IPO Date:
Fiscal Year End: December
Full Time Employees: 9
Back to stocks